EU Panel Backs Novo Hemophilia A Drug and AZ Offerings
Europe's drug advisory body issued positive opinions for a batch of medicines, including a next-generation hemophilia A therapy from Novo Nordisk and new products from AstraZeneca.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a wave of positive recommendations for new medicines, according to a report from Fierce Pharma. The endorsements cover a range of therapies and include notable products from Novo Nordisk and AstraZeneca.
Among the highlighted decisions was a positive opinion for Novo Nordisk's next-generation treatment for hemophilia A. The therapy is designed to offer a new option for patients with the bleeding disorder, though the source does not provide specific efficacy or safety details.
AstraZeneca also had new offerings backed by the committee, according to the report. The CHMP's recommendations are typically followed by formal approval from the European Commission, which grants marketing authorization across the EU.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.